ClinicalTrials.gg
CompletedNCT01040871Updated Jan 13, 2014Results posted

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of VELCADE and Rituximab in Diffuse Large B-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-13.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
4th of 26
164 · median 35
Started
2010
with 3 others
Phase 2
13 of 29
none open now
Registered
18th of 29
by date
Lead sponsor
2 of 29
Millennium Pharmaceuticals, Inc.

Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2010, is one of 13 in phase 2, and was the 18th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse as a file.
02

Study summary

This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Non-Germinal Center B-Cell (non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 years or older.
  • Newly Diagnosed non-GCB subtype of DLBCL (Stage II, III or IV).
  • At least 1 measurable site of disease.
  • (ECOG) performance status 0-2
  • Female subjects must be (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of before entry and throughout the study; and have a negative pregnancy test at screening.
  • Male subjects must agree to use a double barrier method of birth control

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with VELCADE.
  • Prior extended radiotherapy or chemotherapy for lymphoma
  • More than 150 mg/m2 of prior doxorubicin
  • Major surgery within 3 weeks of study.
  • Peripheral neuropathy or neuralgia of Grade 2 or worse.
  • Active CNS lymphoma
  • Diagnosed or treated for a other than NHL, with some exceptions
  • Pregnant or breast feeding
  • Active systemic infection
  • Documented of suspected (HIV)/AIDS
  • Uncontrolled or severe cardiovascular disease
  • Known allergies, or intolerance to study drugs
  • Serious medical condition that could interfere with study
  • Concurrent treatment with another agent
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    VR-CAP

    VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.

    Drug: VELCADE · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

  • Active comparator
    R-CHOP

    R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Vincristine

Interventions

  • VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.

  • Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

  • Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

  • Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

  • Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles

  • Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate

    Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. 1. Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. 2. PET scan was negative. 3. The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared. 4. If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy. 5. No new sites of disease were detected.

    Time frame: 6 cycles

Secondary outcomes

  1. Overall Response Rate

    Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.

    Time frame: 6 cycles

  2. Rate of Durable Response

    Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.

    Time frame: Median follow up approx. 12 months

  3. Rate of Durable Complete Response

    Proportion of subjects who achieved a CR with duration of at least 6 months

    Time frame: Median follow up approx 12 months

  4. Subsequent Anti-lymphoma Therapy Rate at 1-year

    Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive.

    Time frame: 1 year

  5. Progression-free Survival (PFS)Rate at 1-year

    Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death.

    Time frame: 1 year

  6. Overall Survival Rate at 1-year

    Kaplan-meier estimate of overall survival at 1-year measured from date of randomization.

    Time frame: 1 year

  7. Change in Fatigue and Patient Utility Scores

    Time frame: 18-24 months

07

Results

Posted Nov 27, 2013

Participant flow

Participant flow — Overall Study
MilestoneVR-CAPR-CHOP
Started8480
Completed7173
Not completed137
Withdrew: Adverse event62
Withdrew: Withdrawal by subject20
Withdrew: Death13
Withdrew: Lack of efficacy11
Withdrew: Drug supply issue10
Withdrew: Randomized and not treated21

Outcome measures

PrimaryComplete Response (CR) Rate

Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. 1. Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. 2. PET scan was negative. 3. The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared. 4. If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy. 5. No new sites of disease were detected.

Time frame:
6 cycles
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsVR-CAPR-CHOP
Complete Response (CR) Rate64.5 (55.4 to 73.5)63.5 (54.3 to 72.7)
Statistical analysis
  • VR-CAP vs R-CHOP · Cochran-Mantel-Haenszel · p = 0.915 · Odds ratio (or): 1.038 · 95% CI 0.529 to 2.037Odds ratio: VR-CAP CR rate relative to R-CHOP CR rate
SecondaryOverall Response Rate

Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.

Time frame:
6 cycles
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsVR-CAPR-CHOP
Overall Response Rate93.4 (88.7 to 98.1)98.6 (96.4 to 100.0)
SecondaryRate of Durable Response

Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.

Time frame:
Median follow up approx. 12 months
Reported as:
Number · percentage of participants
Rate of Durable Response
percentage of participantsVR-CAPR-CHOP
Rate of Durable Response53.9 (44.5 to 63.4)67.6 (58.6 to 76.5)
SecondaryRate of Durable Complete Response

Proportion of subjects who achieved a CR with duration of at least 6 months

Time frame:
Median follow up approx 12 months
Reported as:
Number · percentage of participants
Rate of Durable Complete Response
percentage of participantsVR-CAPR-CHOP
Rate of Durable Complete Response44.7 (35.3 to 54.1)47.3 (37.7 to 56.9)
SecondarySubsequent Anti-lymphoma Therapy Rate at 1-year

Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive.

Time frame:
1 year
Reported as:
Number · percentage of participants
Subsequent Anti-lymphoma Therapy Rate at 1-year
percentage of participantsVR-CAPR-CHOP
Subsequent Anti-lymphoma Therapy Rate at 1-year71.1 (57.9 to 80.8)80.2 (68.8 to 87.9)
SecondaryProgression-free Survival (PFS)Rate at 1-year

Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death.

Time frame:
1 year
Reported as:
Number · percentage of partipants
Progression-free Survival (PFS)Rate at 1-year
percentage of partipantsVR-CAPR-CHOP
Progression-free Survival (PFS)Rate at 1-year78.9 (67.2 to 86.8)83.9 (72.7 to 90.8)
SecondaryOverall Survival Rate at 1-year

Kaplan-meier estimate of overall survival at 1-year measured from date of randomization.

Time frame:
1 year
Reported as:
Number · percentage of partipants
Overall Survival Rate at 1-year
percentage of partipantsVR-CAPR-CHOP
Overall Survival Rate at 1-year94.1 (84.6 to 97.8)84.2 (73.2 to 91.0)
SecondaryChange in Fatigue and Patient Utility Scores
Time frame:
18-24 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VR-CAP—31/82 (37.8%)73/82 (89%)
R-CHOP—27/79 (34.2%)72/79 (91.1%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventVR-CAPR-CHOP
Febrile neutropeniaBlood and lymphatic system disorders7/827/79
NeutropeniaBlood and lymphatic system disorders4/825/79
PyrexiaGeneral disorders5/820/79
PneumoniaInfections and infestations4/823/79
Lung infectionInfections and infestations2/820/79
DiarrhoeaGastrointestinal disorders2/820/79
DyspnoeaRespiratory, thoracic and mediastinal disorders2/820/79
Pleural effusionRespiratory, thoracic and mediastinal disorders2/820/79
HypotensionVascular disorders2/820/79
VertigoEar and labyrinth disorders2/820/79
Most frequent other events
Showing 10 of 29
Most frequent other events
EventVR-CAPR-CHOP
ConstipationGastrointestinal disorders24/8225/79
Peripheral sensory neuropathyNervous system disorders23/8215/79
FatigueGeneral disorders21/8211/79
AnaemiaBlood and lymphatic system disorders19/8217/79
Oedema peripheralGeneral disorders14/825/79
CoughRespiratory, thoracic and mediastinal disorders14/8211/79
Decreased appetiteMetabolism and nutrition disorders13/825/79
DyspepsiaGastrointestinal disorders11/827/79
Back painMusculoskeletal and connective tissue disorders11/826/79
AlopeciaSkin and subcutaneous tissue disorders10/824/79

Baseline characteristics

Intent to Treat, Randomized

Age, Continuous
Age, Continuous(years)VR-CAPR-CHOPTotal
Mean56.5 ± 15.0057.8 ± 13.8357.2 ± 14.41
Sex: Female, Male
Sex: Female, Male(Participants)VR-CAPR-CHOPTotal
Female433376
Male414788
Region of Enrollment
Region of Enrollment(participants)VR-CAPR-CHOPTotal
Russian Federation221436
Turkey41216
Korea, Republic of6612
Malaysia538
Canada336
India246
Brazil235
Argentina213
Singapore213
Mexico011
Germany13821
Portugal5712
Italy268
Czech Republic347
Spain527
France246
Belgium415
Ireland202
08

Study locations

1 site
  • Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie
    Gent, Belgium
09

References and documents

Publications

  • Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015 Oct 15;126(16):1893-901. doi: 10.1182/blood-2015-03-632430. Epub 2015 Jul 31. PubMed 26232170 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2009
First posted
Dec 30, 2009
Start
Jan 2010
Primary completionActual
Jun 2012
CompletionActual
Aug 2012
Results first posted
Nov 27, 2013
Last update
Jan 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01040871
Responsible party
Sponsor
First posted
Dec 30, 2009
Start date
Jan 2010
Primary completion
Jun 2012
Completion
Aug 2012
Results posted
Nov 27, 2013
Last update
Jan 13, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion